Taro Pharmaceutical Industries Ltd. has received approval from the USFDA for its ANDA for Levetiracetam Tablets, 250 mg, 500 mg, 750 mg and 1000 mg. Taro's levetiracetam tablets is a prescription product used in the treatment of epilepsy, and is bioequivalent to UCB's Keppra® Tablets. According to industry sources, levetiracetam tablets had U.S. sales of over $700 million in 2009.
No comments:
Post a Comment